Skip to main content
Premium Trial:

Request an Annual Quote

Nitto Denko Advances RNAi Fibrosis Drug into Phase Ib

Premium

NEW YORK (GenomeWeb) – Japan's Nitto Denko announced this month that it has initiated a Phase Ib study of its siRNA-based fibrosis treatment ND-L02-s0201, just months after the drug successfully completed a Phase Ia safety study in healthy volunteers.

ND-L02-s0201 comprises siRNAs targeting heat shock protein 47, a collagen-specific chaperone required for the biosynthesis and secretion of collagen, and is delivered using vitamin A-coupled lipid nanoparticles. The drug's payload is based on siRNA technology Nitto Denko licensed from Quark Pharmaceuticals in 2010.

The open-label Phase Ib trial, which is being run in the US in collaboration with contract research firm RRD International, is set to enroll up to 24 patients with moderate to extensive hepatic fibrosis. Participants will receive doses of ND-L02-s0201 either once a week or twice a week for five consecutive weeks, and then be observed through week 24.

The study is designed to evaluate the safety and efficacy of the therapy.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more